Related Experiment Video
Updated: May 26, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Rosiglitazone and fenofibrate additive effects on lipids
Ahmad Slim1, Laudino Castillo-Rojas, Eddie Hulten
1Cardiology Service, Brooke Army Medical Center, San Antonio, TX 78234-6200, USA.
Cholesterol
|December 14, 2011
Summary
Fenofibrate, alone or with rosiglitazone, significantly reduced triglycerides and apolipoprotein C-III levels in healthy adults. Rosiglitazone alone did not impact triglyceride levels, suggesting it doesn't independently treat hypertriglyceridemia.
Area of Science:
- Cardiovascular Pharmacology
- Metabolic Research
Background:
- Investigating the effects of rosiglitazone and fenofibrate on plasma lipids.
- Assessing the combined impact of these drugs in normoglycemic adults.
Purpose of the Study:
- To determine the efficacy of rosiglitazone, fenofibrate, or their combination in altering lipid profiles.
- To evaluate changes in triglycerides, HDL-C, LDL-C, and specific apolipoproteins.
Main Methods:
- Double-blind, randomized trial involving 41 healthy adults.
- Treatment arms included rosiglitazone monotherapy, fenofibrate monotherapy, combination therapy, and placebo.
- Lipid and apolipoprotein levels were measured after 12 weeks.
Main Results:
- Fenofibrate (alone or combined with rosiglitazone) significantly reduced triglyceride levels (47-55 mg/dL).
- Rosiglitazone monotherapy did not significantly alter triglyceride levels.
- Apolipoprotein C-III levels decreased significantly with fenofibrate-containing regimens.
- Apolipoprotein A-II levels increased across all treatment groups compared to placebo.
Conclusions:
- Fenofibrate demonstrates efficacy in lowering triglycerides and Apo C-III in normoglycemic individuals.
- Rosiglitazone's effect on triglycerides appears dependent on glucose metabolism, not independent.
- Combined therapy shows benefits comparable to fenofibrate monotherapy for triglyceride reduction.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...